|Bid||29.45 x 100|
|Ask||29.49 x 300|
|Day's Range||29.29 - 30.03|
|52 Week Range||24.82 - 41.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2018 - Mar 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.78|
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.
GlaxoSmithKline's (GSK) application to include treatment of eosinophilic granulomatosis with polyangiitis in Nucala's label was approved by the FDA.
Proteostasis (PTI) stock skyrockets on positive results from early and mid-stage studies on its cystic fibrosis pipeline candidates.
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that Damien McDevitt, Ph.D., has joined ACADIA as Senior Vice President, Corporate Development, leading the company’s corporate development activities.
Jim Cramer dove into one “wild trader” in the biotech space and why he thinks it’s worth speculating on in a pullback.
Lilly's (LLY) gastric cancer drug, Cyramza, meets primary endpoint of progression free survival in a phase III study in first-line advanced gastric cancer patients. However, it failed to improve overall survival.
One sector group in particular looks ready to profit from the upward drift are the biotech stocks, which have been on the decline in recent weeks as investors focus on Big Tech stocks and more recently on high-tax issues most likely to benefit from the GOP’s corporate tax cut plans.
NEW YORK, NY / ACCESSWIRE / December 6, 2017 / U.S. markets slumped Tuesday as the recent sell of technology stocks continued. The Dow Jones Industrial Average declined 0.45 percent to close at 24,180.64, ...
Nuplazid's sales are soaring, but Acadia's stock price hasn't responded in kind. Is that mismatch creating a buying opportunity for investors?
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
NEW YORK, Nov. 30, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.
ACADIA Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017, at 10:00 a.m.
Hedge fund titan Dmitry Balyasny is founder of the eponymous $12.6 billion Balyasny Asset Management (BAM) fund, which has now revealed its trades for the third quarter.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
ACADIA Pharmaceuticals (NASDAQ:ACAD) just yielded a third quarter outclass that has one of the Street's top analysts impressed in the upshot. What commercial success does Cowen analyst Ritu Baral spot ahead for the biotech player's Parkinson's disease psychosis asset Nuplazid?
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / U.S. markets pushed higher Wednesday on the strength of corporate earnings on the anniversary of President Trump's election. The Dow Jones Industrial Average ...